<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10070890</article-id><article-id pub-id-type="pmc">2362691</article-id><article-id pub-id-type="pii">6690146</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690146</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq&#x02122; (nolatrexed dihydrochloride) given by 10-day oral administration</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jodrell</surname><given-names>D I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bowman</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rye</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Byrne</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Boddy</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rafi</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>G A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Clendeninn</surname><given-names>N J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><aff id="aff1">1ICRF Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, UK</aff><aff id="aff2">Cancer Research Unit, University of Newcastle, Framlington Place, Newcastle upon Tyne, UK</aff><aff id="aff3">Agouron Pharmaceuticals, 10350 N. Torrey Pines Road, La Jolla, CA, 92037-1020, USA</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>ICRF Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, UK</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>5-6</issue><fpage>915</fpage><lpage>920</lpage><history><date date-type="received"><day>06</day><month>04</month><year>1998</year></date><date date-type="rev-recd"><day>27</day><month>05</month><year>1998</year></date><date date-type="accepted"><day>22</day><month>06</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq, AG337), a specific inhibitor of thymidylate synthase, was developed using protein structure-based drug design. Intravenously administered nolatrexed is active clinically. As oral bioavailability is high (70&#x02013;100&#x00025;), nolatrexed was administered orally, 6 hourly for 10 days, at 3-week intervals, and dose escalated from 80 to 572 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>in 23 patients. Common toxicity criteria (CTC) grade 3 toxicities included nausea, vomiting, stomatitis and liver function test (LFT) abnormalities. Thrombocytopenia (grade 1 or 2) occurred at doses &#x02265; 318 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>and neutropenia (grade 2) at 429 and 572 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>. An erythematous maculopapular rash occurred at dosages &#x02265; 318 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>(7 out of 19 patients). LFT abnormalities occurred in two out of six patients (grade 3 or 4 bilirubin and grade 3 alanine transaminase) at 572 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>. Nolatrexed plasma concentrations 1 h after dosing were 6&#x02013;16 &#x003bc;g ml<sup>&#x02212;1</sup>, and trough 3&#x02013;8 &#x003bc;g ml<sup>&#x02212;1</sup>, at 572 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>. Inhibition of thymidylate synthase was demonstrated by elevation of plasma deoxyuridine. Six-hourly oral nolatrexed for 10 days was associated with antiproliferative effects, but nausea and vomiting was dose limiting at 572 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>. Nine patients were treated at 429 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>; three out of nine experienced grade 3 nausea, but 17 out of 22 treatment courses were completed (with the co-administration of prophylactic antiemetics) and this dose level could be considered for phase II testing. <italic>1999 Cancer Research Campaign</italic></p></abstract><kwd-group><kwd>nolatrexed</kwd><kwd>oral</kwd><kwd>10-day administration</kwd><kwd>phase I</kwd></kwd-group></article-meta></front></article>
